Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.

The Journal of pharmacology and experimental therapeutics - 1 Nov 1991

Turgeon J, Fiset C, Giguère R, Gilbert M, Moerike K, Rouleau J R, Kroemer H K, Eichelbaum M, Grech-Bélanger O, Bélanger P M

Abstract excerpt

Mexiletine is a low clearance drug which undergoes extensive metabolism in man. In vitro studies with human liver microsomes have suggested that major oxidation pathways of mexiletine are predominantly catalyzed by the genetically determined debrisoquine 4-hydroxylase (cytochrome P450IID6) activity. In this study, we investigated the role of debrisoquine polymorphism and the effects of low dose quinidine, a...

Topics

Administration, Oral
Adult
Debrisoquin
Dose-Response Relationship, Drug
Drug Interactions
Female
Humans
Male
Phenotype
Polymorphism, Genetic
Quinidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 1941626

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-1941626-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.PMID 1941626Read ↗

Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.Semantic proximity Read ↗

Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.Semantic proximity Read ↗

Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.Semantic proximity Read ↗

Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.Semantic proximity Read ↗

The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.Semantic proximity Read ↗

Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.Semantic proximity Read ↗

Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.Semantic proximity Read ↗

The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.Semantic proximity Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)-metoprolol.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.